For Psychedelics, US FDA Is Open To Creative Thinking But Firm On Approval Standards

Listen to this article

Flexible thinking and rigorous standards will both be needed to develop psychedelics as drug therapies in order to surmount the many complicating factors, from unique ‘set and setting’ aspects to functional unblinding, speakers at Reagan-Udall Foundation meeting agree.

Psychedelic drugs present unique challenges to the conventional drug development paradigm, so it is fitting that a more unconventional or creative package of clinical trials could make for a more successful NDA than the traditional ideal of two replicate randomized pivotal trials.

Key Takeaways

From dose response to maintenance assessment, trials for psychedelic drugs will likely be very different from other psychiatric drugs, even if the approval standards are the same.

“Our regulations are inherently flexible, and the exact types of studies that are needed to provide this data aren’t specified,”...

For Psychedelics, US FDA Is Open To Creative Thinking But Firm On Approval Standards

Key Takeaways

More from Approval Standards

PS-Pathways&Standards (Free-1): Industrial Chemicals Within Us - The Ubiquity of Industrial Products in the Human Body

Diversity Action Plans: What To Submit And When

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

Califf: Rare Disease Hub Will Develop Methods To Guide Approvability Determinations

More from Pathways & Standards

Anvisa To Access US FDA-Reviewed Data For More Robust Evaluations In Brazil

Califf: Rare Disease Hub Will Develop Methods To Guide Approvability Determinations

Primary Biliary Cholangitis Drug Confirmatory Trials Aim To Avoid Hurdles That Tripped Up Ocaliva

For Psychedelics, US FDA Is Open To Creative Thinking But Firm On Approval Standards

Key Takeaways

Learn what's happening at the US FDA. On the go.

More from Approval Standards

More from Pathways & Standards